News and Trends 2 Nov 2022
CV6 Therapeutics raises $9.2M to test cancer drug
…Northern Ireland to support the phase 1a trial. First-in-class CV6 Therapeutics is developing CV6-168, a novel, first-in-class DNA uracilation agent that selectively targets the enzyme dUTPase. Cancer cell DNA uracilation…